Rituximab's new therapeutic target: the podocyte actin cytoskeleton.
Level V
Where this comes from
- Record sourced from PubMed, PMID 21632983.
- Also identified by DOI 10.1126/scitranslmed.3002429.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Therapeutic off-target activities are well recognized for small-molecule drugs. In contrast, monoclonal antibodies (mAbs) traditionally are believed to act specifically and lack off-target therapeutic effects. In this issue of Science Translational Medicine, Fornoni et al. show therapeutic benefit, through an off-target-mediated mechanism, of the mAb drug rituximab in recurrent focal segmental glomerulosclerosis (FSGS) after kidney transplantation. These data shed new light on FSGS pathogenesis and suggest new therapeutic interventions for proteinuric diseases.
Medical subject headings
- Antibodies, Monoclonal, Murine-Derived
- Glomerulosclerosis, Focal Segmental
- Podocytes